Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Applied Molecular Transport Inc.AMTI · Entity 95737 | Director | May 24, 2022 | May 26, 2022 |
| Lucira Health, Inc.LHDX · Entity 115613 | Director | June 01, 2022 | June 03, 2022 |
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Applied Molecular Transport Inc.
Report date May 24, 2022 · Filed May 26, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 · Expires 2032-05-24 | Direct | 20,000 |
Reported balance
After 2022-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-24 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% of the stock option granted on May 24, 2022 will become vested on the earlier of (i) May 24, 2023 or (ii) the business day prior to the date of the 2023 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the stock option granted on May 24, 2022 will become vested on the earlier of (i) May 24, 2023 or (ii) the business day prior to the date of the 2023 annual meeting of stockholders.
Lucira Health, Inc.
Report date June 01, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2032-05-31 | Direct | 59,459 |
Reported balance
After 2022-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-01 · Grant · Acquired 59,459 · Balance 59,459 F1: The shares subject to this option will vest upon the earlier of the one year anniversary of the grant date of June 1, 2022 or immediately prior to the next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest upon the earlier of the one year anniversary of the grant date of June 1, 2022 or immediately prior to the next annual meeting.
Quince Therapeutics, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-06-11 | Direct | 2,700 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 2,700 · Balance 2,700 F1: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2020 Filed May 19, 2020 22:41 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 5,906 | $55.42 | $327,308.75 |
DisclosureSEC source: 0001209191-20-030688 · doc4.xml · nonDerivative · entry 8 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,665,090 F8 · price: The range of prices for the shares of Common Stock is from $54.895 to $55.77. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| May 19, 2020 Filed May 19, 2020 22:41 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 400 | $54.09 | $21,636.00 |
DisclosureSEC source: 0001209191-20-030688 · doc4.xml · nonDerivative · entry 7 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,659,184 F7 · price: The range of prices for the shares of Common Stock is from $53.65 to $54.53. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| May 15, 2020 Filed May 19, 2020 22:41 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 100 | $53.10 | $5,310.00 |
DisclosureSEC source: 0001209191-20-030688 · doc4.xml · nonDerivative · entry 6 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,658,784 F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| May 15, 2020 Filed May 19, 2020 22:41 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 500 | $52.20 | $26,100.50 |
DisclosureSEC source: 0001209191-20-030688 · doc4.xml · nonDerivative · entry 5 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,658,684 F6 · price: The range of prices for the shares of Common Stock is from $51.95 to $52.57. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| May 15, 2020 Filed May 19, 2020 22:41 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 1,000 | $50.71 | $50,707.30 |
DisclosureSEC source: 0001209191-20-030688 · doc4.xml · nonDerivative · entry 4 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,658,184 F5 · price: The range of prices for the shares of Common Stock is from $50.38 to $51.36. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| May 15, 2020 Filed May 19, 2020 22:41 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 1,600 | $48.96 | $78,333.44 |
DisclosureSEC source: 0001209191-20-030688 · doc4.xml · nonDerivative · entry 3 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,657,184 F4 · price: The range of prices for the shares of Common Stock is from $48.70 to $49.625. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| May 15, 2020 Filed May 19, 2020 22:41 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 985 | $48.37 | $47,639.53 |
DisclosureSEC source: 0001209191-20-030688 · doc4.xml · nonDerivative · entry 2 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,655,584 F3 · price: The range of prices for the shares of Common Stock is from $47.68 to $48.64. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| May 15, 2020 Filed May 19, 2020 22:41 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 1,263 | $46.30 | $58,477.78 |
DisclosureSEC source: 0001209191-20-030688 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,654,599 F1 · price: The range of prices for the shares of Common Stock is from $45.80 to $46.75. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 23:18 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantCommon Stock | 30,000 | $50.00 | $1,500,000.00 |
DisclosureSEC source: 0001209191-20-008073 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,653,336 F1 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 924,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029476 · doc4.xml · derivative · entry 5 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 0 Underlying: Common Stock · 924,056 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Mr. Lamond is the trustee of the Blue Devil Trust dated 12/03/2010, and holds sole voting and dispositive power with respect to the shares held of record by Blue Devil Trust dated 12/03/2010. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 301,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029476 · doc4.xml · derivative · entry 4 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 301,829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 699,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029476 · doc4.xml · derivative · entry 3 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 0 Underlying: Common Stock · 699,280 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Mr. Lamond is the trustee of the Blue Devil Trust dated 12/03/2010, and holds sole voting and dispositive power with respect to the shares held of record by Blue Devil Trust dated 12/03/2010. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | ConversionCommon Stock | 301,829 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-029476 · doc4.xml · nonDerivative · entry 2 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | ConversionCommon Stock | 1,623,336 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-029476 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,623,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock. F2 · price: Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Mr. Lamond is the trustee of the Blue Devil Trust dated 12/03/2010, and holds sole voting and dispositive power with respect to the shares held of record by Blue Devil Trust dated 12/03/2010. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.